News from Holden


Sarcoma outcomes improve at high-volume centers.

Sarcoma patients treated at high-volume medical centers may have higher survival rates than those treated at low-volume centers.


Holden announces CAR T-cell therapy.

Holden is now certified to offer CAR T-cell therapy, a newly approved treatment that uses a patient’s own white blood cells to detect and kill cancer cells.


Hawkeyes and Cyclones work side by side in unique cancer research project.

Cancer researchers at two Iowa universities are collaborating on research to address cancer similarities in humans and their companion animals.


The incidence of HPV cancers is increasing in Iowa.

While the overall number of new cancer cases in Iowa remains mostly unchanged, the number of cancers related to the human papillomavirus (HPV) is on the rise.


Study suggests new approach to treating kids with relapsed cancer.

The study’s findings may provide insight on new approaches or combination therapies to improve other forms of chemotherapy and limit side effects.


Neuroendocrine tumor program earns high European distinction.

The European Neuroendocrine Tumor Center of Excellence designation demonstrates Holden’s full commitment to neuroendocrine tumor care and prevention.